Kairos Pharma Announces Positive Interim Results from Phase 2 Trial of ENV105 in Advanced Prostate Cancer, Set to Present at ESMO 2025
Reuters
Oct 07, 2025
<a href="https://laohu8.com/S/KAPA">Kairos Pharma</a> Announces Positive Interim Results from Phase 2 Trial of ENV105 in Advanced Prostate Cancer, Set to Present at ESMO 2025
Kairos Pharma Ltd. has announced that it will present data from a Phase 2 clinical trial evaluating the safety and efficacy of apalutamide in combination with carotuximab (ENV105) in patients with advanced, castration-resistant prostate cancer (mCRPC) at the European Society for Medical Oncology (ESMO) Congress, scheduled to take place in Berlin, Germany, from October 17-21, 2025. The ongoing randomized trial is enrolling 100 men with mCRPC who have progressed on prior hormone therapies, with participants receiving apalutamide either with or without ENV105. Interim results from the study will be highlighted during the presentation, focusing on preliminary safety and clinical activity. Further details about the trial can be found at https://clinicaltrials.gov/study/NCT05534646.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kairos Pharma Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251007913966) on October 07, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.